BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ginsberg GM, Block C, Stein-Zamir C. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel. Int J Public Health 2016;61:683-92. [PMID: 27105884 DOI: 10.1007/s00038-016-0821-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. Value Health 2021;24:91-104. [PMID: 33431159 DOI: 10.1016/j.jval.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Delgado Rodríguez M, Domínguez García Á. Pros y contras de la vacunación frente a la enfermedad por meningococo B. Medicina Clínica 2018;150:109-13. [DOI: 10.1016/j.medcli.2017.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Stein-Zamir C, Shoob H, Abramson N, Block C, Keller N, Jaffe J, Valinsky L. Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines. Hum Vaccin Immunother 2019;15:242-8. [PMID: 30156954 DOI: 10.1080/21645515.2018.1507261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ginsberg GM, Chemtob D. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. BMC Public Health 2020;20:271. [PMID: 32103750 DOI: 10.1186/s12889-020-8334-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Christensen H, Al-Janabi H, Levy P, Postma MJ, Bloom DE, Landa P, Damm O, Salisbury DM, Diez-Domingo J, Towse AK, Lorgelly PK, Shah KK, Hernandez-Villafuerte K, Smith V, Glennie L, Wright C, York L, Farkouh R. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ 2020;21:297-309. [PMID: 31754924 DOI: 10.1007/s10198-019-01129-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
6 Breton MC, Huang L, Snedecor SJ, Cornelio N, Fanton-Aita F. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada. Can J Public Health 2020;111:182-92. [PMID: 31907760 DOI: 10.17269/s41997-019-00275-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Salama M, Kopel E, Jaffe J, Amitai Z, Sheffer R, Rahmani S, Yuabov I, Dardik L, Valinsky L. Surveillance of invasive meningococcal disease in the Tel Aviv District, Israel, 2007-2017. Vaccine 2019;37:6186-91. [PMID: 31495596 DOI: 10.1016/j.vaccine.2019.08.055] [Reference Citation Analysis]
8 Nwogu IB, Jones M, Langley T. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review. Vaccine 2021;39:2201-13. [PMID: 33744052 DOI: 10.1016/j.vaccine.2021.02.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nagi MA, Luangsinsiri C, Thavorncharoensap M. A systematic review of economic evaluations of vaccines in Middle East and North Africa countries: is existing evidence good enough to support policy decision-making? Expert Rev Pharmacoecon Outcomes Res 2021;:1-20. [PMID: 34252335 DOI: 10.1080/14737167.2021.1954508] [Reference Citation Analysis]
10 Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Isr J Health Policy Res 2018;7:63. [PMID: 30554570 DOI: 10.1186/s13584-018-0258-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]